Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites.

In a search for new ligands selective for the estrogen receptor beta (ERbeta), we prepared a series of non-steroidal compounds having an isocoumarin core structure. An interesting feature of these derivatives is that they bear the same functionalities as the well-known ERbeta -selective, isoflavone phytoestrogens daidzein and genistein, but in an isomeric arrangement. These compounds could be prepared efficiently by electrophilic cyclization of acetylenic ester precursors, followed by simple manipulations to introduce additional substituents. Through a reduction of some of the isocoumarins, we also obtained isomeric analogs of the isoflavone metabolites equol and dehydroequol. The compounds we prepared were evaluated in ER binding assays, and selected compounds were studied further in cell-based gene transcription assays. Several of the isocoumarins and their analogs are high-affinity ligands that show considerable selectivity for ERbeta in terms of binding affinity, and strikingly high ERbeta selectivity in terms of potency in gene transcription assays. Two of the best compounds, which combine high transcriptional potency with an ERbeta selectivity greater than 1000, should prove to be excellent probes of ERbeta function in vivo.

[1]  J. Gustafsson,et al.  Update on estrogen signaling , 2003, FEBS letters.

[2]  Fabio Stossi,et al.  Indazole estrogens: highly selective ligands for the estrogen receptor beta. , 2005, Journal of medicinal chemistry.

[3]  Li‐Ping Sun,et al.  Chemistry of aminophenols. Part 1: Remarkable additive effect on Sonogashira cross-coupling of 2-carboxamidoaryl triflates and application to novel synthesis of indoles , 2001 .

[4]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[5]  B. Katzenellenbogen,et al.  Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. , 2003, Molecular endocrinology.

[6]  G. C. Fu,et al.  Pd/P(t-Bu)(3): a mild and general catalyst for Stille reactions of aryl chlorides and aryl bromides. , 2002, Journal of the American Chemical Society.

[7]  G. Firestone,et al.  Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.

[8]  Qing‐Yun Chen TRIFLUOROMETHYLATION OF ORGANIC HALIDES WITH DIFLUOROCARBENE PRECURSORS , 1995 .

[9]  B. Katzenellenbogen,et al.  Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Zamani,et al.  Total synthesis of homalicine and its related dihydro aglycon , 2000 .

[11]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[12]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[13]  E. Napolitano,et al.  Influence of alkoxyalkyl substituents in the regioselective lithiation of the benzene ring , 1983 .

[14]  R. Karas,et al.  The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.

[15]  R. Gandour,et al.  The identity of 4-bromo-3-phenylisocoumarin. A facile preparation by bromolactonization of alkyl 2-(2-phenylethynyl)benzoates , 1984 .

[16]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[17]  K E Carlson,et al.  Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. , 1997, Biochemistry.

[18]  R. Larock,et al.  Synthesis of Isocoumarins and α-Pyrones via Electrophilic Cyclization , 2003 .

[19]  R. Rossi,et al.  New procedures for the selective synthesis of 2(2H)-pyranone derivatives and 3-aryl-4-iodoisocoumarins , 2002 .

[20]  R. Grubbs,et al.  Safe and Convenient Procedure for Solvent Purification , 1996 .

[21]  B. Katzenellenbogen,et al.  Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. , 2004, Bioorganic & medicinal chemistry.

[22]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Komm,et al.  Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .

[24]  L. Mannina,et al.  Synthesis of 3-arylisocoumarins, including thunberginols A and B, unsymmetrical 3,4-disubstituted isocoumarins, and 3-ylidenephthalides via iodolactonization of methyl 2-ynylbenzoates or the corresponding carboxylic acids , 2003 .

[25]  Eric S Manas,et al.  Structure-based design of estrogen receptor-beta selective ligands. , 2004, Journal of the American Chemical Society.

[26]  C. Behl Oestrogen as a neuroprotective hormone , 2002, Nature Reviews Neuroscience.